In the previous paper, we discussed why traditional conjoint approaches overburden respondents in pharma market research – and how overburdened respondents give unreliable results. In this paper, we explore the impact of sample size on reliability, the challenges of recruiting enough respondents to drown out the noise, and how a fit-for-pharma conjoint platform solves these challenges.
